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Although expanded polyglutamine (polyQ) repeats are inherently toxic, causing at least nine neurodegenerative diseases, the protein
context determines which neurons are affected. The polyQ expansion that causes Huntington’s disease (HD) is in the first exon (HDx-1)
of huntingtin (Htt).However, otherparts of theprotein, including the 17N-terminal aminoacids and twoproline (polyP) repeat domains,
regulate the toxicity ofmutantHtt. The role of theP-rich domain that is flankedby the polyPdomains has not been explored.Usinghighly
specific intracellular antibodies (intrabodies), we tested various epitopes for their roles in HDx-1 toxicity, aggregation, localization, and
turnover. Three domains in the P-rich region (PRR) of HDx-1 are defined by intrabodies:MW7 binds the two polyP domains, andHapp1
and Happ3, two new intrabodies, bind the unique, P-rich epitope located between the two polyP epitopes. We find that the PRR-binding
intrabodies, aswell asVL12.3,whichbinds theN-terminal 17aa, decrease the toxicity andaggregationofHDx-1, but theydosobydifferent
mechanisms. The PRR-binding intrabodies have no effect onHtt localization, but they cause a significant increase in the turnover rate of
mutantHtt,whichVL12.3doesnot change. In contrast, expressionofVL12.3 increasesnuclearHtt.Wepropose that thePRRofmutantHtt
regulates its stability, and that compromising this pathogenic epitope by intrabody binding represents a novel therapeutic strategy for
treating HD. We also note that intrabody binding represents a powerful tool for determining the function of protein epitopes in living
cells.
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Introduction
Huntington’s disease (HD) is an autosomal dominant, progres-
sive, neurodegenerative disorder that results from the expansion
of a polyglutamine (polyQ) tract in the first exon (HDx-1) of
huntingtin (Htt) (The Huntington’s Disease Collaborative Re-
search Group, 1993). At least nine other neurodegenerative dis-
eases are caused by the expansion of a polyQ tract, including
several types of spinocerebellar ataxia (Orr et al., 1993; Kawagu-
chi et al., 1994; Imbert et al., 1996; David et al., 1997), denta-
torubral pallidoluysian atrophy (Koide et al., 1994), and spinob-
ulbar muscular atrophy (La Spada et al., 1991). In each case, the
polyQ expansion is in a different protein, and although the mu-
tant protein is expressed widely, only a specific subset of neurons
unique to each disease die. Although expression of pure polyQ is
sufficient to cause toxicity (Marsh et al., 2000; Yang et al., 2002),
it is the protein context surrounding the polyQ expansion that
makes particular neurons susceptible in each disease. In HD, the
mutant protein exhibits toxic gain of function, which includes
aggregation, sequestering of important cellular proteins such as
transcription factors, and aberrant protein–protein interactions,
including disruption of the ubiquitin proteasome (Duyao et al.,
1995; Ross, 1997; Wanker, 2000; Jana et al., 2001; Ramaswamy et
al., 2007). This leads to chorea, dementia, and loss of medium
spiny striatal as well as some cortical neurons (Reddy et al., 1999;
Zoghbi and Orr, 2000; Nakamura and Aminoff, 2007). HDx-1
consists of 17 N-terminal amino acids followed by the polyQ
tract, the P-rich region (PRR), which consists of two polyP
stretches that are separated by a P-rich domain, and 13 additional
amino acids (Fig. 1A). The non-polyQ domains in HDx-1 are
known to modulate the toxicity of the mutant protein, although
the mechanisms by which this occurs are not well understood
(Duennwald et al., 2006). Understanding how these non-polyQ
domains contribute to the toxicity and specificity of mutant Htt
(mHtt) could lead to new therapeutic strategies.
Classically, the function of a protein domainwould be studied
by removal of that domain followed by functional testing. Al-
though a great deal of knowledge has been acquired through such
methods, the deletion of a domain may cause altered folding of
the remaining protein or otherwise generate effects not related
directly to the function of the missing domain. Perturbation of a
protein domain by intrabody binding is a more specific method
for exploring function. Intrabodies are intracellular, recombi-
nant, single-chain antibody fragments (scFv) that contain the
heavy and light antigen-binding domains (VH andVL) connected
by a linker. Alternatively, single-domain antibody fragments
consist of either VH or VL. Intrabodies are highly specific reagents
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that can be targeted to subcellular com-
partments, distinct protein conforma-
tions, posttranscriptional modifications,
and nonprotein targets such as oligosac-
charides (Biocca and Cattaneo, 1995;
Stocks, 2005;Messer andMcLear, 2006; Lo
et al., 2008). Intrabodies thus have great
potential to increase our understanding of
the functions of individual protein do-
mains in living cells.
We sought to use intrabodies to better
understand the role of the polyP and
P-rich domains (the PRR) of Htt in HD
pathology. The PRR is known to be impor-
tant for mHtt toxic gain of function (Pas-
sani et al., 2000; Steffan et al., 2000; Mo-
dregger et al., 2002; Khoshnan et al., 2004;
Qin et al., 2004), and although a number
of binding partners, including WW
domain-containing proteins, vesicle-
associated proteins, P53, and IKK, have
been identified, the mechanism of the
modulation of mHtt toxicity by these do-
mains remains unclear. The role of the
P-rich domain is not known. To investi-
gate this aspect of PRR function, we used
MW7, an scFv intrabody that binds polyP.
MW7 reduces mHtt-induced aggregation
and promotes cell survival in culture
(Khoshnan et al., 2002). It also inhibits
mHtt-induced neurodegeneration in a
Drosophila HD model (Jackson et al., 2004). However, the spec-
ificity of this intrabody for pure polyP could allow binding to
other cellular proteins containing a polyP domain, although
there is no evidence of the latter binding to date. To characterize
the role of the PRR, we produced novel intrabodies (Happs)
against the P-rich domain of Htt. Happ1 and Happ3 are single-
domain, light chain intrabodies (VLs) that bind mHtt in a PRR-
dependentmanner.We then tested theHapps,MW7 andVL12.3,
a single-domain light chain intrabody that binds the 17
N-terminal amino acids of Htt (Colby et al., 2004b), for efficacy
in blocking mHDx-1 aggregation and toxicity, as well as their
effects on subcellular localization and mHDx-1 protein levels.
The most striking findings are that both the anti-polyP and anti-
P-rich intrabodies reduce toxicity by increasing mHtt turnover
and lowering themHtt levels, whereas the anti-N-terminal intra-
body appears to reduce mHtt toxicity by a different mechanism.
Materials andMethods
Cell culture.HEK293 (American Type Culture Collection) or ST14A stri-
atal precursor (Cattaneo, 1998) cells were grown in DMEM (Invitrogen)
supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glu-
tamine, 1 mM streptomycin, and 100 U of penicillin (Invitrogen). Cells
weremaintained in 37°C (HEK293) or 33°C (ST14A) incubatorswith 5%
CO2 unless otherwise stated. Transfections were performed using Lipo-
fectamine 2000 transfection reagent (Invitrogen) according to the man-
ufacturer’s protocol.
Immunoblotting. Protein concentration was determined using a BCA
assay (Pierce). Seventy-five micrograms of total protein per sample in a
volume of 30 l was combined with 6 l of 6 protein loading buffer
(Ausubel et al., 1993) and boiled for 5 min. Samples were separated by
SDS-PAGE using 4–20% criterion precast gels (Biorad) and Precision
Plus Protein Kaleidoscope molecular weight standard (Bio-Rad). Sam-
ples were then transferred overnight to nitrocellulose membranes for
immunoblotting. Appropriate primary and horseradish peroxidase
(HRP)-conjugated secondary antibodies were then applied as described
by Ausubel et al. (1993). SuperSignal West Dura (Pierce) substrate was
applied tomembranes according to themanufacturer’s protocol. Chemi-
luminescence was detected and densitometry was performed using a
FluorChem 8900 (Alpha Innotech) gel documentation system.
Selection of phage display library for binding to P-rich epitope of Htt.
Intrabodies were selected from the Griffin.1 human recombinant, scFv
phage display library (Griffiths et al., 1994). One well of a six-well plate
was coated with a synthetic peptide (200 g/ml) derived from the P-rich
epitope of Htt (PQLPQPPPQAQP) located between the two polyP
stretches by incubating at 4°C overnight. The coated well was then used
to select phage-expressing intrabodies specific for this epitope according
to the provider’s instructions. After the fourth round of selection, the
P-rich enriched phage library was purified by polyethylene glycol/NaCl
precipitation and suspended in 2 ml of PBS.
Generation of bait peptide for isolation of Happ intrabodies. A plasmid
encoding PQ50-glutathione S-transferase (GST) (Scherzinger et al.,
1997) was transformed into XL-10 gold ultracompetent bacteria (Strat-
agene) according to the manufacturer’s protocol. Cells were grown to an
OD of 0.6 at 600 nm and induced with 1 mM isopropyl -D-1-
thiogalactopyranoside for 4 h. Bacteria were collected by centrifugation,
andGST fusion proteinswere isolated in 1ml of 50%Glutathione Sepha-
rose bead slurries containing bound peptide (Ausubel et al., 1993).
Twenty-five microliters of each bead slurry were added to 10 l of pro-
tein loading buffer, boiled for 5 min, and separated by SDS-PAGE. Pep-
tide expression was verified by Coomassie staining of PAGE gels and
comparison to a protein molecular weight marker (data not shown).
Selection of Happ intrabodies from P-rich-specific phage display library.
One milliliter of the preselected P-rich-specific phage was selected with
PQ50-GST as described in the library provider’s instructions. Briefly,
GST-fusion bait peptide bound to glutathione agarose beads was incu-
bated with replication-deficient phages displaying preselected, P-rich
scFvs and then washed in PBS with 0.1% Triton X-100 to remove any
unbound phage particles. Bound phages were allowed to infect log phase
Figure 1. The anti-Htt intrabodies reduce mHDx-1-induced toxicity and aggregation in cell culture. A, The epitopes in HDx-1
for the various intrabodies are depicted. B, To quantify mHtt toxicity, HEK293 cells were cotransfected with mHDx-1-GFP and
intrabody at various intrabody/Htt ratios and incubated for 48 h. Cells were stainedwith EthD-2 to identify dead cell nuclei, fixed,
and stainedwithDAPI to identify all cell nuclei. Thenumberof dead cellswasnormalized to total cell number. All of the intrabodies
reducemHDx-1-induced cell death in a saturable, dose-dependentmanner,withmaximal effects at different intrabody/Htt ratios
(1:1 for VL12.3, 2:1 for Happ1 andHapp3, and 4:1 forMW7). C, Aggregationwas determined by countingGFP foci and normalizing
to total cell number. *Different fromVL12.3 at p 0.05; **p 0.01. The point labeled as 0 on the intrabody:Htt axis corresponds
to the value for HDx-1 CVL.
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bacteria. To repeat selection, M13 helper phages, which do not display
scFvs but enable the replication of scFv-displaying phages from prein-
fected bacteria, were used to recover selected phages. This selection was
repeated an additional two times. After the final round of selection, in-
dividual clones were selected and screened for inserts by the PCR(Grif-
fiths et al., 1994). Six cloneswith inserts were identified (Happ1–Happ6).
Inserts were sequenced and analyzed for open reading frames (ORFs).
Three clones were found to contain ORFs, two of which were redundant.
The two unique ORFs (Happ1 andHapp3) were amplified by PCR using
primers designed to add both appropriate restriction sites and a
C-terminal hemagglutinin (HA) epitope tag, and cloned into the adeno-
associated virus genome plasmid (AAV) (Stratagene) mammalian ex-
pression vector for characterization in cell culture, and into the pGEX-
6p1 GST fusion (GE Healthcare) bacterial expression vector for protein
purification. A control intrabody that does not bind HDx-1 (CVL) was
also isolated from the library and cloned into these vectors. Cloning was
performed according to the Invitrogen One Shot Top10 competent cell
protocol.
Htt aggregation and toxicity assays. HEK293 cells were cotransfected
with HDx-1-green fluorescent protein (GFP) and intrabody in poly-D-
lysine-coated 24-well plates at60% confluency. Each well received 0.2
g of PQ103 DNA in pcDNA3.1 vector and intrabody (VL12.3, MW7,
Happ1, Happ3, or CVL) DNA in AAV vector at various ratios to HDx-1
(0.5:1, 1:1, 2:1, 3:1, and 4:1). DNA levels were normalized to 1g per well
using CVL in AAV vector. Nontransfected wells were used as a negative
control, and each condition was performed in triplicate. Cultures were
moved to a 33°C incubator 8 h after transfection to slow cell division and
maintain a monolayer. At 40 h after transfection, cells were incubated in
medium containing 1 mM ethidium homodimer-2 (EthD-2) (Invitro-
gen) for 15 min at 33°C for detection of dead cell nuclei. Cells were then
fixed in 4% PFA at 4°C for 30 min and permeabilized with PBS contain-
ing 0.1% Triton for 15 min. For detection of all nuclei, cells were treated
with PBS containing 0.5g/ml 4,6-diamidino-2-phenylindole (DAPI).
Fluorescence microscopy was used to visualize dead cells (red channel),
large Htt aggregates (green channel), and total cell number (blue chan-
nel). Three representative microscope fields were analyzed for each well
(nine per condition). Dead cells and aggregates were counted for each
field and normalized to the total cell number. p values were computed
using a Student’s t test.
Brain slice neurodegeneration assay. All animal experiments were per-
formed in accordance with the Institutional Animal Care and Use Com-
mittee and Duke University Medical Center Animal Guidelines. Brain
slice preparation and biolistic transfection were performed as previously
described (Lo et al., 1994; Khoshnan et al., 2004). Briefly, brain tissue was
dissected from CD Sprague Dawley rats killed on postnatal day 10 (P10)
(Charles River Laboratory) and placed in ice-cold culture medium con-
taining 15% heat-inactivated horse serum, 10 mM KCl, 10 mM HEPES,
100 U/ml penicillin/streptomycin, 1 mM sodium pyruvate, and 1 mM
L-glutamine in Neurobasal A (Invitrogen). Brain tissue was cut into 250-
m-thick coronal slices using a Vibratome and incubated for 1 h at 37°C
under 5.0% CO2 before biolistic transfection. Gold particles (1.6 m
gold microcarriers; Bio-Rad) were coated with the appropriate DNAs
(see below) as per themanufacturer’s instructions and loaded into Tefzel
tubing (McMaster-Carr) for use with the Helios biolistic device (Bio-
Rad), which was used at a delivery pressure of 95 psi. Gold particles were
coated with expression constructs encoding yellow fluorescent protein
(YFP) as amorphometricmarker, cyan fluorescent protein (CFP)-tagged
mHDx-1 Q-73, and the relevant intrabody; for control transfections,
particles were coated with YFP CVL, YFPmHDx-1Q73 and vector
backbone DNA, or YFP  mHDx-1Q73  CVL. For each condition,
transfections were done on 12 brain slices, and numbers of healthy me-
dium spiny neurons (MSNs) expressing the YFP reporter were assessed
4–5 d after brain slice preparation and transfection using fluorescence
microscopy. MSNs with normal-sized cell bodies, even and continuous
expression of YFP in the cell body and dendrites, and having more than
two discernable primary dendrites more than two cell bodies long were
scored as healthy. p values were computed using a Student’s t test.
Immunohistochemical HDx-1 localization. ST14A cells were grown in
six-well plates containing coverslips and cotransfected with HDx-1-GFP
and intrabody in six-well plates at60% confluency. Each well received
1 g of PQ103 and intrabody DNA at optimal ratios. Nontransfected
wells were used as a negative control. At 48 h after transfection, cells were
fixed and permeabilized as described above. Intrabodies were then la-
beled usingM2 anti-Flag forMW7 and 3F10 anti-HA for VL12.3, Happ1,
and Happ3. Secondary antibodies were conjugated to Alexa Fluor 568
(Invitrogen) (Hockfield et al., 1993). Cells were processed for micros-
copy as above. Mean fluorescence intensity for whole-cell and nuclear
HDx-1 (green channel) and intrabody (red channel) was measured in
threemicroscope fields perwell. The ratio of nuclearHDx-1 or intrabody
to cellular HDx-1 or intrabody was determined by (mean intensity of
nucleus/mean intensity of whole cell). p values were computed using a
Student’s t test.
HDx-1 immunoblot assay.HEK293 cells were cotransfectedwithHDx-
1-GFP and intrabody in 10 cm dishes at 80% confluency. Each dish
received 4g of PQ103 or PQ25DNA in pcDNA3.1 vector and intrabody
DNA in AAV vector at the optimal ratio for each intrabody (4 g of
VL12.3, 16 g of MW7, 8 g of Happ1 and Happ3). A nontransfected
dish was used as a negative control. Cells were dislodged by mechanical
dissociation and pipetting 48 h after transfection, harvested by centrifu-
gation, washed with PBS, and lysed by sonication in 500l of lysis buffer
(25mMHEPES, 50mMNaCl, 1 mMMgCl2, and 0.5% Triton) containing
1 Complete, Mini, EDTA-free Protease Inhibitor Cocktail tablet (Roche)
per 7 ml of buffer. The soluble protein fraction was collected by centrif-
ugation for 20 min at 4°C at 20,000  g. The insoluble pellet was soni-
cated in 150 l of 6 M urea and incubated for 20 min at room tempera-
ture. Immunoblots were then performed using rabbit anti-GFP (1:1000;
Invitrogen) as primary antibody and HRP-conjugated, goat anti-rabbit
(1:10,000; Santa Cruz Biotechnology) as secondary antibody to detect
HDx-1-GFP. For a loading control, membranes were stripped using Re-
store Western blot stripping buffer (Pierce) and reprobed with mouse
anti--tubulin (1:1000; Sigma) as primary and HRP-conjugated, goat
anti-mouse (1:10,000; SantaCruzBiotechnology) as secondary antibody.
Densities of HDx-1 and -tubulin bands were determined. Each HDx-1
band was normalized to the level of the -tubulin band for that sample.
The ratio of HDx-1 level in the presence of intrabody to HDx-1 level
alone was determined by (density of intrabody plus HDx-1/density of
intrabody plus HDx-1 tubulin)/(density of HDx-1 alone/density of
HDx-1 alone tubulin). The experiment was repeated three additional
times, giving an n of 4. p values were computed using a Student’s t test.
HDx-1 turnover assay. ST14A cells were grown in six-well plates con-
taining coverslips and cotransfected withHDx-1-SNAP and intrabody at
60% confluency. Each well received 1 g of either PQ97-SNAP (97Q-
HDx-1 fused to the SNAP tag) or PQ25-SNAP (25Q-HDx-1 fused to the
SNAP tag) DNA in pSEMXT-26m vector (Covalys Witterswil) and in-
trabody DNA in AAV vector at optimal ratios (1 g of VL12.3, 4 g of
MW7, 2 g of Happ1 and Happ3). Nontransfected wells were used as a
negative control, and each condition was performed twice. To covalently
label HDx-1 present at 24 h after transfection, cells were treated with
decay-accelerating factor (DAF) green fluorescent SNAP-substrate (Co-
valys Witterswil) according to the manufacturer’s protocol. After label-
ing, cells were handled in low light conditions to avoid photobleaching
the DAF substrate. One well of each condition was then fixed and per-
meabilized as described above. For detection of all nuclei, cells were
treated with blocking solution (3%BSAw/v, 10%NGS, and 0.1%Triton
X-100 in PBS) containing 1:2000 Toto-3 iodide (Invitrogen). Coverslips
were then mounted with Prolong gold anti-fade reagent (Invitrogen).
The remaining well of each condition was incubated for an additional
24 h (48 h after transfection) to allow turnover of labeled HDx-1, and
processed for microscopy as above. Mean fluorescence intensity of indi-
vidual cells was observed in three microscope fields per well using LCS
software (Leica). Mean cellular fluorescence intensities were computed
for both 24 and 48 h conditions. The percentage of labeledHDx-1 at 24 h
and remaining at 48 h was determined by [(mean intensity at 48 h/mean
intensity at 24 h) 100]. The experiment was repeated three additional
times, giving an n of 4. p values were computed using a Student’s t test.
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Results
Isolation of Happ intrabodies
Novel intrabodies against the PRR domain were selected in a
two-stage protocol. First, a nonimmune, human recombinant
scFv phage library (Griffin.1) (Griffiths et al., 1994) was used to
select clones that bind a unique, P-rich sequence between the two
polyP domains in mHDx-1. The second stage involved three
rounds of selection using PQ50 (HDx-1 containing 50 Q and the
PRR) (Scherzinger et al., 1997). After the second stage, individual
clones were analyzed for inserts containing ORFs. Although the
Griffin.1 library consists of full scFv fragments, the two clones
selected had only the VL ORFs. A control VL that does not bind
Htt (CVL) was also isolated from the library. These three VLs
(Happ1, Happ3, and CVL) were then inserted into a mammalian
expression vector for cell culture and brain slice studies. To verify
the specificity of these intrabodies, they were expressed as GST
fusion proteins and used as primary antibodies to stain mem-
branes containing the lysates of HEK293 cells transfected with
HDx-1 or HDx-1PRR. The lysates of nontransfected cells were
used to test for binding non-Htt cellular proteins (supplemental
Fig. S1, available at www.jneurosci.org as supplemental mate-
rial). As expected, MW7 and the Happs bind only to HDx-1
containing the PRR, whereas VL12.3 binds both forms of HDx-1.
None of the intrabodies bind the nontransfected lysates. These
results confirm that the Happs require the Htt PRR epitope for
binding.
The intrabodies reduce mHDx-1 aggregation and toxicity
Each of the intrabodies was tested at various ratios to mHDx-1
(0.5:1, 1:1, 2:1, 3:1, and 4:1) for effects on mHDx-1 toxicity by
counting EthD-2-positive dead cell nuclei (Fig. 1B), and aggre-
gation by counting green foci of the HDx-1-GFP fusion protein
(Fig. 1C). Whereas VL12.3, Happ1, and Happ3 demonstrate
dose-dependent, saturable beneficial effects on aggregation,
MW7 demonstrates a threshold effect requiring a 4:1 ratio for
benefit. This may be the result of its specificity for pure polyP.
Because there are twopolyP stretches that can each accommodate
binding of two intrabody molecules, reduction of aggregation by
polyP binding may require complete blockade of these epitopes.
Interestingly, this does not appear to be the case for the toxicity
induced by mHDx-1. The VL12.3 intrabody is the most effective
in reducing toxicity, with an optimal ratio to mHDx-1 of 1:1.
MW7 is optimal at a ratio of 4:1, whereas Happ1 andHapp3 each
show an optimal ratio of 2:1, with significant beneficial effects at
1:1. Similar effects on mHDx-1-induced toxicity were seen when
measuring lactate dehydrogenase activity (data not shown).
These results confirm previous findings with the N1-17 aa
epitope and further demonstrate that the PRR also regulates
HDx-1 toxicity. Because CVL shows no dose-dependent effects
(data not shown), the median ratio of 2:1 was used as a baseline
level of mHDx-1-induced toxicity or aggregation (Fig. 1B, zero
point).
The intrabodies reduce mHDx-1-induced neurodegeneration
in a corticostriatal brain slice model of HD
Rat brain slices, which preserve much of the intrinsic neural cir-
cuitry, were biolistically cotransfected with YFP, mHDx-1-CFP,
and an intrabody. The number of morphologically healthy,
transfected MSNs in the striatum of each slice was then assessed
using YFP fluorescence as an independent reporter of cell type
and vitality 4–5 d after slice preparation and transfection (Fig. 2).
The number of healthy MSNs per brain slice was compared be-
tween a positive control (brain slices transfected with YFP 
CVL), a negative control (transfected with YFP  mHDx-1 
vector backbone DNA), and the test condition (transfected with
YFP  mHDx-1  anti-Htt intrabody). Cotransfection of
mHDx-1 with CVL results in significantly reduced numbers of
healthy MSNs, as is seen in slices transfected with mHDx-1 and
vector. In contrast, cotransfection of mHDx-1 with VL12.3 or
Happ1 results in numbers of healthy MSNs that are similar to
slices transfected with YFP  CVL. Cotransfection of slices with
mHDx-1  MW7 yields intermediate results, with significantly
greater numbers of healthyMSNs thanwithmHDx-1CVL, but
fewer than with YFP  CVL. These results extend the findings
from HEK293 cells to MSNs in a semi-intact milieu.
Figure 2. Protective effects of anti-Htt intrabodies against mHDx-1-induced neurodegen-
eration in corticostriatal brain slice explants. Corticostriatal brain slices were biolistically trans-
fected with plasmid expression constructs encoding YFP, mHDx-1 (N1–66 with 73 Q), and the
indicated intrabody. The number of healthymedium spiny neurons in the striatal region of each
slice was scored visually 4–5 d after slice preparation and transfection. A, Slices were trans-
fectedwithYFPCVL; YFPCVLmHDx-1; YFPmHDx-1VL12.3; or YFPmHDx-1
Happ1. *Different from YFP CVL at p 0.01.B, Sliceswere transfectedwith YFP CVL; YFP
 vector (Vec)mHDx-1; YFPCVLmHDx-1; or YFPmHDx-1MW7. *p0.01. The
data in A and B are from independent experiments.
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VL12.3 alters cytoplasmic versus nuclear trafficking
of mHDx-1
To evaluate the effect of the intrabodies on HDx-1 intracellular
trafficking, ST14A striatal neuronal precursor cells were cotrans-
fected with mHDx-1-GFP and intrabody and incubated for 48 h.
Cells were fixed, stained for both intrabody and nuclei, and then
mounted for analysis by confocal microscopy. GFP fluorescence
intensity was used to compare levels of mHDx-1 in the whole cell
versus the nucleus (Fig. 3). The PRR-binding intrabodies do not
alter the cytoplasmic/nuclear mHDx-1 ratio, whereas VL12.3
causes a dramatic increase of nuclear Htt. In terms of localization
of the intrabodies themselves, VL12.3, Happ1, andHapp3 display
a slight preference for the nucleus, whereasMW7 is slightly more
cytoplasmic (supplemental Fig. S2, available at www.
jneurosci.org as supplemental material). This could be the result
of the larger size of the MW7 scFv compared with the single-
domain intrabodies. No significant differences are seen between
VL12.3, Happ1, and Happ3, and the slight preference of VL12.3
for the nucleus is too small to account for the increased nuclear
HDx-1 in the presence of VL12.3, indicating that this change in
localization is not the result of intrabody localization. Thus, in-
trabody binding to the N terminus of Htt disrupts cytoplasmic
versus nuclear trafficking of Htt, which may influence its nuclear
functions. Because the amount of nuclear mHtt correlates with
toxicity (Truant et al., 2007), this result suggests that VL12.3 may
not be ideal as a therapeutic intrabody despite its clear effects on
blocking mHtt toxicity.
The intrabodies differentially alter the level of
soluble mHDx-1
To determine the effects of the intrabodies on mHDx-1 levels,
HEK293 cells were cotransfected with intrabody and either wild-
type HDx-1 (wtHDx-1) or mHDx-1, using each intrabody at its
optimal ratio to HDx-1, and incubated for 48 h. Soluble and
insoluble cell fractions were then assayed forHDx-1 by immuno-
blotting and densitometry (Fig. 4). Each of the intrabodies dra-
matically reduces the level of insoluble mHDx-1. However, the
three PRR-binding intrabodies (MW7, Happ1, and Happ3) also
significantly reduce the level of soluble mHDx-1, whereas VL12.3
has no significant effect on soluble mHDx-1 or wtHDx-1 levels.
From a therapeutic standpoint, it is important that only a slight
reduction of wtHDx-1 protein is seen, indicating that anti-PRR
intrabodies are selective for the mutant form. Although these
intrabodies bind wtHDx-1, their preference for the mutant form
is not unexpected as the interaction of endogenous Htt PRR-
binding partners with Htt is known to increase with increasing
polyQ repeat length (Passani et al., 2000; Holbert et al., 2001).
The PRR-binding intrabodies increase mHDx-1 turnover
To further investigate the reduction of soluble mHDx-1, a SNAP
tag fusion labeling experiment was performed (Jansen et al.,
2007). A traditional pulse chase experiment was not used because
mHDx-1 is known to affect transcriptional regulation. This prop-
erty of mHDx-1 could conceivably be altered by intrabody bind-
ing, leading to variable transcription rates of HDx-1 in the pres-
ence of the various intrabodies. Traditional pulse-chase
experiments require equal transcription and translation of the
target protein in all conditions within the labeling period. The
SNAP tag fusion system allows labeling of all preexisting HDx-1.
Bymeasuring the amount of Htt at the time of labeling and again
at a later time point, we are able to measure a rate of turnover
independent of transcription or translation rate. This system also
offers greater specificity, because only the SNAP tag fusion pro-
tein is labeled as opposed to all cellular proteins translated during
the labeling period as with traditional pulse-chase experiments.
To investigate HDx-1 turnover using the SNAP tag fusion
system, HEK293 cells were cotransfected with intrabody and
HDx-1 fused to the SNAP tag. Twenty-four hours after transfec-
tion, HDx-1 was labeled using a fluorescent, cell-permeable
SNAP substrate. This substrate undergoes a covalent binding re-
action with the SNAP tag and remains fluorescent until the
SNAP-tag fusion protein is broken down. Some cultures were
immediately examined for HDx-1 levels, whereas others were
incubated for 48 h after transfection to allow turnover of labeled
HDx-1. Fluorescence intensity of HDx-1-SNAP was used to de-
termine the percentage of HDx-1 labeled at 24 h that is still intact
at 48 h (Fig. 5). Cells transfected with HDx-1-SNAP alone were
used to determine a baseline level of turnover. Although the per-
centage ofmHDx-1 remaining in the presence of VL12.3 is equiv-
alent to that in the control, this percentage is significantly re-
duced in the presence of MW7, Happ1, or Happ3, indicating an
Figure 3. VL12.3 increases the level of nuclear HDx-1. ST14A cells were cotransfected with
mHDx-1-GFPwith 103Q and intrabody at optimal ratios.A, At 48 h after transfection, cells were
fixed, stained for the appropriate intrabody and cell nuclei, and analyzed by confocal micros-
copy. B, Mean whole-cell fluorescence intensity (int.) and mean nuclear fluorescence intensity
of HDx-1 were compared. Whereas MW7, Happ1, and Happ3 have no effect on HDx-1 localiza-
tion, VL12.3 significantly increases nuclear HDx-1. *Different from HDx-1 at p 0.01.
Southwell et al. • Proline-Rich Domains of mHtt Increase Stability J. Neurosci., September 3, 2008 • 28(36):9013–9020 • 9017
increase in the rate of mHDx-1 turnover
specifically in the presence of the PRR-
binding intrabodies (Fig. 5B). The lack of
effect of VL12.3 provides a convenient
control for nonspecific effects of intrabody
binding to mHDx-1. Although the mech-
anismbywhich this increase inmHtt turn-
over occurs is not yet clear, the levels of
intrabody protein are increased in the
presence of mHtt (data not shown), sug-
gesting that mHtt is not broken down as a
part of a complex with intrabody. This
novel ability of PRR-binding intrabodies
to increase turnover of mHtt suggests that
this region of the protein is important for
stability. Further evidence of the specificity
of the intrabody effects is shown by the fact
that none of the anti-Htt intrabodies sig-
nificantly changes the rate of wtHDx-1
turnover (Fig. 5C).
Discussion
Although anti-N-terminal and anti-PRR
intrabodies ameliorate the negative effects
of mHtt in cell culture and brain slice
models of HD, they do so with different
efficacy and by different mechanisms.
These different mechanisms offer clues to
the specific functions of their target
domains.
The VL12.3 intrabody was isolated
froma yeast surface display library and ini-
tially required a 5:1 ratio tomHtt to reduce
aggregation (Colby et al., 2004a). It was then reengineered, in-
cluding removal of the disulfide bonds, which do not form in the
reducing environment of the mammalian cytoplasm [and can
cause misfolding of intrabodies (Biocca et al., 1995)], and mu-
tated for greater binding affinity to Htt (Colby et al., 2004b). In
addition to inhibitingmHtt-induced toxicity and aggregation,we
find that VL12.3 also alters cytoplasmic versus nuclear trafficking
of HDx-1.
Modulation of Htt intracellular targeting by the N terminus
has been recently characterized. Removal of this amphipathic 
helix causes an increase in the level of nuclear Htt, indicating that
Figure 4. All of the anti-Htt intrabodies reduce insoluble HDx-1, whereas only the anti-PRR intrabodies also reduce soluble HDx-1. HEK293 cells were cotransfected with intrabody andmHDx-1
(76 kDa) or wtHDx-1 (40 kDa) at the optimal ratio for each intrabody. A, At 48 h after transfection, cells were lysed with detergent. The soluble protein fraction was recovered, and the insoluble
fractionwas treatedwith urea. Samples were then separated by SDS-PAGE and blotted for HDx-1. Nontransfected cells were used as a negative control (NEG).B, Quantification of bands shows that
reduction of HDx-1 by PRR-binding intrabodies is significantly greater for themutant formof Htt. Chemiluminescence densitometrywas used to compare the levels of solublemHDx-1 andwtHDx-1.
Each bandwas normalized to the level of-tubulin (54 kDa) in that sample. Bands for HDx-1 intrabody (iAb)were then normalized to the level of soluble HDx-1 for that blot. n 4 independent
experiments, and values for each blot were used to compile a mean. *p 0.01.
Figure 5. Anti-PRR intrabodies increase mHDx-1 turnover. A–C, ST14A cells were transfected with mHDx-1-SNAPtag 97Q (A,
B) or wtHDx-1-SNAPtag 25Q (C) and intrabody at the optimal ratio for each intrabody. DAF green fluorescent SNAP substratewas
added to cultures at 24hafter transfection. Somecultureswere then fixedand stainedwith Toto-3 iodidenuclearmarker,whereas
others were incubated an additional 24 h to allow turnover of labeled HDx-1. Mean fluorescence intensity of cells at 24 h was
compared with intensity at 48 h to determine the percentage of labeled HDx-1 remaining. VL12.3 has no effect on mHDx-1 or
wtHDx-1 turnover, whereas MW7, Happ1, and Happ3 significantly increase the rate of mHDx-1 turnover. n 4; *p 0.01.
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it functions as a cytoplasmic retention signal (Rockabrand et al.,
2007). Mutation of hydrophobic residues, or the introduction of
a helix-breaking proline residue in theN-terminal domain results
in increased nuclearHtt, suggesting that cytoplasmic retention by
the N terminus is the result of association with organelle and
vesicle membranes (Atwal et al., 2007). Although the N terminus
is not a dimerization domain, disruption of the helical structure
also prevents the aggregation of mHtt, which is accompanied by
an increase in the toxicity of the protein. Thus, the N terminus of
Htt is required for cytoplasmic localization and the formation of
aggregates. The effect on toxicity seen in these experiments may
be related to the prevention of aggregation, because mHtt-
expressing neuronswithout aggregates exhibitmore toxicity than
those with aggregates (Arrasate et al., 2004). Toxicity related to
the N terminusmay also involve altered Htt localization, because
the addition of a nuclear localization signal to mHtt increases its
toxicity in both cell culture and mouse models of HD (Peters et
al., 1999; Schilling et al., 2004). Interestingly, whereas removal or
mutation of the N terminus results in increased toxicity, VL12.3
binding results in reduced toxicity, suggesting that VL12.3 may
inhibit formation of a toxic conformation or an oligomerization
seed molecule. Thus, this intrabody may ameliorate toxicity re-
gardless of mHtt localization or aggregation state.
The polyP and P-rich domains of mHtt are implicated in a
number of aberrant protein interactions. These domains are re-
quired for mHtt binding to, and sequestering of, several SH3
domain-containing proteins, including proteins associated with
vesicle function (Modregger et al., 2002; Qin et al., 2004). The
PRR of Htt is required for interaction with WW domain-
containing proteins (Staub and Rotin, 1996; Faber et al., 1998).
These include transcription factors, and these interactions are
enhanced with increased polyQ repeat length (Passani et al.,
2000; Holbert et al., 2001). These domains are the site of interac-
tion with IKK, a regulatory subunit of the IB kinase complex.
Activation of this complex is known to promote aggregation and
nuclear localization of mHtt (Khoshnan et al., 2004). The PRR of
Htt is also the site of P53 interaction and is required for transcrip-
tional repression of P53-regulated genes (Steffan et al., 2000).
Again, this interaction is enhanced by increased polyQ repeat
length.
MW7, an intrabody recognizing pure polyP, reduces mHtt-
induced aggregation and toxicity in cell culture and inDrosophila
models of HD (Khoshnan et al., 2002; Jackson et al., 2004). We
find that it is also effective in an acute brain slice model of HD,
and that it increases the turnover of HDx-1, with greater effect on
the mutant than the wild-type form. We also produced novel
intrabodies, Happ1 and Happ3, which recognize the unique,
P-rich epitope between the two polyP domains of Htt. The Happ
intrabodies exhibit beneficial properties similar to those ofMW7,
such as preferential effects on the mutant form of Htt and in-
creasing turnoverwithout altering localization, but theHapps are
effective at lower ratios to Htt thanMW7.We found no evidence
that the anti-PRR intrabodies bind to previously aggregated
mHtt, suggesting that the observed reduction in aggregation is
the indirect result of increased turnover of the soluble form of the
protein, causing a shift away from the aggregated state. The in-
creased turnover ofHDx-1 in the presence of either anti-polyP or
anti-P-rich intrabodies suggests that this effect is a direct result of
blocking these epitopes and therefore that this domain has a role
in modulating stability of the mutant protein.
Disruption of mHtt stability by Happ binding could have
therapeutic potential. The success of RNA interference (RNAi)
experiments show that reduction of mHtt levels is an effective
therapeutic strategy (Harper et al., 2005; Rodriguez-Lebron et al.,
2005; Machida et al., 2006). Unlike RNAi however, these intra-
bodies can distinguish between the wt and mutant forms of Htt,
which is preferable, because the loss of normal Htt function can
have negative effects (Dragatsis et al., 2000; Leavitt et al., 2001;
Zuccato et al., 2001). The ability of the Happ intrabodies to in-
crease turnover of mHtt may ameliorate the disruption of the
ubiquitin proteasome seen inHD, although it is presently unclear
if this increased turnover occurs through a ubiquitin-dependent
pathway. Because the levels of intrabody protein are increased in
the presence of Htt, it is likely that the intrabodies direct the
breakdown of mHtt without themselves being degraded. More-
over, the Happs, although significantly more effective than the
original intrabody isolated and matured to become VL12.3, have
yet to undergo any reengineering and could potentially be im-
proved by removal of disulfide bonds and mutation for greater
Htt binding affinity. In addition, the present results with the
Happ intrabodies highlight the importance of the unique, P-rich
domain in mHtt toxicity.
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